BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 11831546)

  • 1. Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus.
    Kovarik JM; Hartmann S; Hubert M; Berthier S; Schneider W; Rosenkranz B; Rordorf C
    J Clin Pharmacol; 2002 Feb; 42(2):222-8. PubMed ID: 11831546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin.
    Hulskotte EG; Feng HP; Xuan F; Gupta S; van Zutven MG; O'Mara E; Wagner JA; Butterton JR
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2582-8. PubMed ID: 23529734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin.
    Mazzu AL; Lasseter KC; Shamblen EC; Agarwal V; Lettieri J; Sundaresen P
    Clin Pharmacol Ther; 2000 Oct; 68(4):391-400. PubMed ID: 11061579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of atorvastatin on the pharmacokinetics of everolimus among kidney transplant recipients.
    Wanitchanont A; Somparn P; Vadcharavivad S; Chancharoenthana W; Townamchai N; Praditpornsilpa K; Avihingsanon Y
    Transplant Proc; 2014; 46(2):418-21. PubMed ID: 24655978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.
    Lilja JJ; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 1999 Aug; 66(2):118-27. PubMed ID: 10460065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
    Jacobson TA
    Am J Cardiol; 2004 Nov; 94(9):1140-6. PubMed ID: 15518608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics.
    Stangier J; Rathgen K; Stähle H; Reseski K; Körnicke T; Roth W
    Am J Cardiovasc Drugs; 2009; 9(1):59-68. PubMed ID: 19178132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies.
    Pasha MK; Muzeeb S; Basha SJ; Shashikumar D; Mullangi R; Srinivas NR
    Biomed Chromatogr; 2006 Mar; 20(3):282-93. PubMed ID: 16143964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study.
    Gerber JG; Rosenkranz SL; Fichtenbaum CJ; Vega JM; Yang A; Alston BL; Brobst SW; Segal Y; Aberg JA;
    J Acquir Immune Defic Syndr; 2005 Jul; 39(3):307-12. PubMed ID: 15980690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of a fixed-dose combination of atorvastatin and metformin extended release versus concurrent administration of individual formulations: a randomized, open-label, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study.
    Kandhwal K; Dey S; Nazarudheen S; Arora R; Reyar S; Thudi NR; Monif T; Singh MK; Rao S
    Clin Drug Investig; 2011 Dec; 31(12):853-63. PubMed ID: 21919543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.
    Neuvonen PJ; Kantola T; Kivistö KT
    Clin Pharmacol Ther; 1998 Mar; 63(3):332-41. PubMed ID: 9542477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin.
    Hsyu PH; Schultz-Smith MD; Lillibridge JH; Lewis RH; Kerr BM
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3445-50. PubMed ID: 11709322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of food on the pharmacodynamics and pharmacokinetics of atorvastatin, an inhibitor of HMG-CoA reductase.
    Whitfield LR; Stern RH; Sedman AJ; Abel R; Gibson DM
    Eur J Drug Metab Pharmacokinet; 2000; 25(2):97-101. PubMed ID: 11112089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients.
    Taylor PJ; Kubler PA; Lynch SV; Allen J; Butler M; Pillans PI
    Ann Pharmacother; 2004 Feb; 38(2):205-8. PubMed ID: 14742751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No pharmacokinetic or pharmacodynamic interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran.
    Sarich TC; Schützer KM; Dorani H; Wall U; Kalies I; Ohlsson L; Eriksson UG
    J Clin Pharmacol; 2004 Aug; 44(8):928-34. PubMed ID: 15286097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites.
    Backman JT; Luurila H; Neuvonen M; Neuvonen PJ
    Clin Pharmacol Ther; 2005 Aug; 78(2):154-67. PubMed ID: 16084850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of pravastatin and atorvastatin on coenzyme Q10.
    Bleske BE; Willis RA; Anthony M; Casselberry N; Datwani M; Uhley VE; Secontine SG; Shea MJ
    Am Heart J; 2001 Aug; 142(2):E2. PubMed ID: 11479481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythromycin coadministration increases plasma atorvastatin concentrations.
    Siedlik PH; Olson SC; Yang BB; Stern RH
    J Clin Pharmacol; 1999 May; 39(5):501-4. PubMed ID: 10234598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of itraconazole on the pharmacokinetics of atorvastatin.
    Kantola T; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 1998 Jul; 64(1):58-65. PubMed ID: 9695720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin.
    Rakotoniaina Z; Guerard P; Lirussi F; Goirand F; Rochette L; Dumas M; Bardou M
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Dec; 374(3):195-206. PubMed ID: 17102939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.